2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5125 Characteristics and outcomes of patients with newly diagnosed FLT3-mutated AML treated with venetoclax-based therapy and without FLT3 inhibitors in induction

Mohammed Ghannam Alharbi, Fellow Adult Hematology, Georgio Medawar, MD2, Naval Daver, MD3, Courtney DiNardo, MD, MSCE4, Musa Yilmaz, MD5, Gautam Borthakur, MD6, Wei Ying Jen, BM BCh, FRCPath7, Eitan Kugler, MD PhD8, Alex Bataller, MD, PhD9, Alexandre Bazinet, MD, MSc10, Sanam Loghavi, MD11, Nicholas Short, MD12, Ghayas C. Issa, MD13, Farhad Ravandi, MD14, Hagop Kantarjian, MD15, Guillermo Garcia-Manero, MD16, Tapan Kadia I, MD17
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background

FMS-like tyrosine kinase 3 (FLT3) mutations, including internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations, occur in approximately 25-30% of newly diagnosed acute myeloid leukemia (AML). FLT3-ITD has historically been associated with high relapse rates and inferior survival. The addition of FLT3 inhibitors (FLT3i) to intensive induction chemotherapy has become standard of care for FLT3 mutated AML. However, not all patients with FLT3-mutated AML receive FLT3i during induction due to drug-drug interactions, insurance delays, comorbidities, or diagnostic lag before mutation results are available. Emerging data suggest that venetoclax-based regimens combined with intensive (IC) or cytarabine-based low-intensity chemotherapy (LIC) may achieve high remission rates even without FLT3i, and that co-mutations such as NPM1 and DNMT3A modulate prognosis independent of FLT3i use. The outcomes of FLT3-mutated AML patients who do not receive FLT3i during induction, particularly in the venetoclax (VEN) era, remain incompletely characterized; we describe this population at our institution.

 

Methods

We retrospectively reviewed patients with newly diagnosed FLT3-mutated AML treated with venetoclax-based therapies at our institution from 2018-2025 who did not receive FLT3i therapy during induction. Baseline characteristics, co-mutations, FLT3 variant allelic frequency (VAF),  induction regimen (IC: cladribine + idarubicin + cytarabine (CLIA) or fludarabine + cytarabine + idarubicin + G-CSF (FLAG-IDA); LIC: cladribine/low-dose cytarabine [Clad/LDAC]), complete response (CR), relapse-free survival (RFS), overall survival (OS), and stem cell transplant (SCT) rates were collected, with outcomes further analyzed by FLT3-ITD subgroup, co-mutation status (NPM1, DNMT3A), and induction intensity.

 

Results

We identified twenty-six patients with FLT3-mutated AML who did not receive FLT3i during induction (7 ITD, 14 TKD, 5 ITD+TKD co-mutated). Median age was 58 years (range 25-74), and 14 (54%) were male. Four patients (15%) had adverse-risk disease, 1 (4%) had complex cytogenetics, and none had therapy-related AML or TP53 mutations. The median VAF of FLT3-ITD was 4% (range 1-43%) and of FLT3-D835 was 8% (range 2-53%).  Co-mutations were common: NPM1 in 19 (73%), DNMT3A in 9 (35%), and combined NPM1+DNMT3A in 8 (31%); among FLT3-ITD patients, NPM1 co-mutation was present in 7 (27%) and NPM1+DNMT3A in 5 (19%). Fifteen of 26 (58%) received IC+VEN (FLAG-IDA or CLIA) and 11 of 26 (42%) received LIC (Clad/LDAC+VEN). The composite CR/CRi rate was 25/26 (96%), with CR in 24/26 (92%) and MRD-negative by flow cytometry in 23/26 (88%). There were a total of 4/26 (15%) relapses (2 had ITD initially [VAF 4% and 43%] and 2 had TKD [VAF<5% and 5%]). No FLT3 mutations were detected at relapse. Median RFS was 52.6 months (95% CI 22.5-not reached [NR]), and median OS was not reached. Sixteen patients (62%) underwent allogeneic stem cell transplant.

Among FLT3-ITD-mutated patients overall (n=12), CR was 11/12 (92%), median RFS 52.4 months (95% CI 12.7-NR), and median OS 59.4 months (95% CI 12.7-NR). FLT3-ITD patients without NPM1 or DNMT3A co-mutation (n=4) achieved CR in 4/4 (100%), with RFS and OS not reached. FLT3-ITD patients co-mutated with both NPM1 and DNMT3A (n=5) had CR in 5/5 (100%), median RFS 58.8 months (95% CI 40.7-NR), and median OS 59 months (95% CI 47.7-NR). Among FLT3-ITD patients receiving IC (n=7: 6 CLIA, 1 FLAG-IDA), CR was 7/7 (100%), median RFS 40.7 months (95% CI 12.7-NR), and median OS 47.4 months (95% CI 12.7-NR). Among those receiving LIC (n=5, all Clad/LDAC alternating with decitabine or azacitidine), CR was 4/5 (80%), with median RFS 52.4 months (95% CI 5.5-NR) and median OS 59.4 months (95% CI 5.5-NR).

 

Conclusion

In this cohort, newly diagnosed FLT3-mutated AML patients who did not receive FLT3i during induction achieved high remission rates and favorable survival when treated with VEN-based IC or LIC regimens. Favorable co-mutation profiles (NPM1, DNMT3A), low rates of adverse-risk cytogenetics and TP53 mutations, and high SCT utilization likely contributed to these outcomes, but these findings suggest that VEN-based backbones may partially mitigate the adverse prognostic impact of FLT3 mutations even without FLT3i, though larger prospective studies are needed to confirm whether FLT3i would provide additional benefit in this favorable-risk subset.

Mohammed Ghannam Alharbi, Fellow Adult Hematology: No relevant conflicts of interest to declare.